
STRO Stock Forecast & Price Target
STRO Analyst Ratings
Bulls say
Sutro Biopharma's positive outlook is underpinned by a recent valuation increase of its product STRO-004, which rose to $50 million from $25 million, reflecting strong preclinical data and anticipation of an Investigational New Drug (IND) filing later this year. Additionally, the company has demonstrated significant improvements in patient outcomes with Tivdak, which has shown enhanced overall survival (OS) and progression-free survival (PFS) metrics, as well as a notable increase in the overall response rate (ORR) compared to traditional chemotherapy. Lastly, the accelerated approval of Tivdak in 2021 for metastatic cervical cancer, with full approval anticipated in 2024, further substantiates the company's growth potential and market position within the biopharmaceutical sector.
Bears say
Sutro Biopharma faces potential challenges in its development of biopharmaceutical products due to the limitations associated with antibodies that bind preferentially to specific conformations, which may hinder effective and uniform tumor targeting. This suboptimal binding could adversely impact the downstream performance of antibody-drug conjugates (ADCs), including critical factors such as internalization, payload delivery, and overall efficacy. Additionally, the reported off-tissue toxicities linked to TF-targeting mechanisms raise concerns regarding the safety profile of the company's products, which could further complicate their commercial viability.
This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares